Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation (NCT01406223), a randomized phase 3 study. The primary outcome is The Amygdala, Anterior Insula, and Medial Prefrontal Cortex Scans Will be Compared to Evaluate Significant Differences.

2. Clinical Question

The study is framed as a mechanistic evaluation: it asks about brain responses that may help characterize how pre-cessation treatments act, rather than reporting a primary clinical smoking-cessation outcome. The registry lists days to first cigarette following quitting smoking as a secondary outcome. It does not provide numerical results for that outcome or for the primary imaging endpoint.

The record describes a randomized, double-masked, parallel-group phase 3 study with enrollment of 282. The brief summary names nicotine patches, varenicline alone, and varenicline paired with bupropion as treatments of interest. The arm descriptions also distinguish nicotine replacement before and after the quit date. The exact treatment schedules are not fully available for every described arm, so the complete clinical comparison cannot be reconstructed from the registry record.

3. Trial Design

This was a randomized, double-masked, parallel-group phase 3 study sponsored by Duke University. The registry lists enrollment of 282 and a completed status. The recorded study start is 2011-07, and primary completion is recorded as 2013-12. The condition is nicotine dependence.

The treatment groups described in the record are varenicline, nicotine patches only, varenicline plus bupropion, and post-quit nicotine replacement therapy. The intervention list additionally identifies placebo varenicline, placebo bupropion, and placebo patch. The registry does not provide a complete description of how every active treatment and placebo was combined within each group. Some arm descriptions are truncated, so full medication schedules and the exact masking arrangements are not reported in the registry record.

The timing of treatment is relevant to the study question. The primary endpoint concerns cue-reactivity scans after 2 weeks of pre-quit treatment. The arm descriptions refer to treatment in relation to a target quit date, including nicotine replacement before or after that date. The available descriptions are not complete enough to establish every group’s full schedule or to compare all treatment exposures precisely.

The primary outcome is a continuous imaging measure expressed as percent BOLD signal change. It is described as mean cue-reactivity signal following pre-quit treatment, controlling for baseline cue-reactivity. Imaging analyses were restricted to participants who completed both scanning sessions and provided usable data. The number included in that analysis, the reasons for missing or unusable scans, and the extent to which this analysis population differed among groups are not reported in the registry record.

Days to first cigarette following quitting smoking is listed as a secondary outcome. The record indicates two outcome measures overall, but it does not provide a numerical primary result, a numerical secondary result, or details of a statistical analysis. Although the study is marked completed, completion status alone does not supply evidence about the magnitude or precision of treatment-group differences.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Of the 282 participants who were consented and screened, 191 were screen fails, 2 withdrew voluntarily before being assigned to a study arm, and 13 were lost to contact between screening and the first study visit. Therefore, only 76 participants were randomized and started the study.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Only participants who completed both scanning sessions and provided useable data were included in imaging analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as The Amygdala, Anterior Insula, and Medial Prefrontal Cortex Scans Will be Compared to Evaluate Significant Differences, measured over change from baseline in whole brain blood-oxygen-level dependent (BOLD) contrast sensitive functional magnetic resonance imaging (fMRI) images collected during a cue-reactivity task following 2 weeks of pre-quit treatment.

The primary endpoint measures cue-reactivity in brain imaging. Specifically, it is the mean blood-oxygen-level dependent (BOLD) signal during a cue-reactivity task, expressed as percent BOLD signal change. The scans were collected after 2 weeks of pre-quit treatment, and the stated analysis controls for baseline cue-reactivity. The named brain regions are the amygdala, anterior insula, and medial prefrontal cortex.

In general, BOLD fMRI is an imaging measure of changes in blood oxygenation associated with brain activity. A cue-reactivity task uses cues relevant to the behavior under study—in this case, smoking—to elicit a measurable response. Comparing post-treatment signal while accounting for baseline signal is intended to distinguish the post-treatment response from differences that were already present at baseline. This is a mechanistic endpoint: it describes an imaging response, not directly whether a participant quit smoking or how long abstinence continued.

The registry title describes comparing scans to evaluate differences, while the endpoint description specifies adjustment for baseline cue-reactivity. However, it does not report the numerical group means, the treatment contrast, a confidence interval, or a p-value. It also does not report whether the named regions were analyzed as separate endpoints or combined into a single measure. Those details are necessary for interpreting the direction, size, and precision of any observed difference.

Only participants who completed both scans and had usable data were included in the imaging analysis. That restriction matters because the endpoint is unavailable for participants without the required scans or usable images. The number analyzed and the handling of missing imaging observations are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The study is described as randomized, double-masked, and parallel-group. In general, randomization assigns participants to treatment groups by chance, helping reduce systematic differences between groups at the start of a study. Masking is intended to limit the influence of treatment knowledge on participants or study personnel, depending on who is masked. A parallel-group design compares groups receiving different assigned regimens over the study period. The registry does not describe the randomization procedure, the people masked, or how masking was maintained.

What does the primary endpoint summarize?

The primary measure is continuous: mean percent BOLD signal change during a cue-reactivity task after 2 weeks of pre-quit treatment. A continuous outcome can take a range of values rather than belonging to a small set of categories. The mean describes a group’s average value. The standard deviation describes the spread of individual values within that group. These are different summaries: a mean describes location, while a standard deviation describes variability.

The endpoint description says the analysis controls for baseline cue-reactivity. In general, a baseline-adjusted comparison estimates a treatment-group contrast while accounting for the outcome measured before the treatment period. Adjustment may help separate the post-treatment comparison from initial differences and can improve precision when baseline values predict later values. The specific statistical model, the baseline variables entered, and the scale of the reported contrast are not reported in the registry record.

How should a treatment contrast and its uncertainty be read?

In general, a treatment contrast expresses the estimated difference between groups on a defined outcome scale. Its sign depends on the order in which groups are compared, and its interpretation depends on what a higher or lower value represents. For an imaging endpoint, a contrast concerns the measured signal; it does not automatically translate into a difference in quitting behavior.

A confidence interval is a range of values compatible with the data and the method used to calculate it. It conveys uncertainty about the estimated contrast: a narrower interval indicates greater precision than a wider interval, all else equal. A p-value describes how compatible the data are with a specified null hypothesis under the statistical model. Neither measure substitutes for the estimated effect’s size or the scientific meaning of the outcome. The registry does not report a treatment contrast, confidence interval, or p-value for the primary endpoint, so none can be interpreted for this study from the recorded results.

Why does over-dispersion matter?

In general, over-dispersion occurs when observed variability is greater than a statistical model expects. If a model assumes less variability than the data contain, its standard errors may be too small and inferential results may appear more precise than warranted. Methods appropriate for over-dispersed outcomes can account for that extra variability. The primary endpoint is described as continuous, with standard deviation as its dispersion measure; the registry does not report an over-dispersion assessment or a model that would permit one to evaluate it. The concept is general and does not imply that over-dispersion occurred in this study.

What do the planning assumptions describe?

The record describes a planning illustration based on the observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It says that the effect to detect is a stated fraction of the observed effect. For time-to-event planning, the illustration uses the total number of events; for other outcomes, it uses participants per arm. The registry record does not provide the observed effect or numerical planning-illustration results, so specific sample-size values cannot be interpreted.

In general, a sample-size calculation estimates the amount of information needed to detect a prespecified effect under stated assumptions. It is a planning exercise, not a measure of how likely the completed study was to detect its actual result. Such calculations depend on assumptions about the outcome, variability, effect size, allocation, and statistical test. The described illustration is explicitly based on the observed effect, which is distinct from a documented design justification. The trial’s own sample-size justification is not reported in the registry record. Any planning illustration based on an observed result would not be observed power.

The record does not report the detailed statistical analysis plan, the model used for the secondary time-to-event outcome, handling of multiple comparisons, or any interim analyses. General statistical methods can explain what such choices mean, but they cannot establish which methods were used in this trial.

10. Multiplicity, Missing Data and Analysis Populations

The registry names three brain regions in the primary endpoint description: the amygdala, anterior insula, and medial prefrontal cortex. It does not report whether these were tested as separate outcomes, combined, or handled in another way. Nor does it report the number of planned treatment contrasts or any adjustment for multiple comparisons. When several outcomes or contrasts are tested, the chance of at least one apparently notable result can increase; methods for managing that issue depend on the prespecified analysis plan. The plan is not reported in the registry record, so the multiplicity approach cannot be assessed.

The record identifies two outcome measures and lists days to first cigarette following quitting smoking as a secondary outcome. It does not report an analysis hierarchy, a prespecified distinction between confirmatory and exploratory comparisons, or numerical results for the secondary outcome. It also does not report interim analyses. These omissions do not show that such plans or analyses did not exist; they are not reported in the registry record.

For the primary imaging analysis, eligibility required completion of both scanning sessions and usable data. This means the stated analysis population excludes participants who did not satisfy those conditions. The number of participants with missing scans or unusable data, reasons for missingness, group-specific analysis counts, and methods for addressing missing data are not reported. In general, complete-case analysis can be difficult to interpret if the probability of having usable data is related to treatment assignment or the outcome. The registry does not provide the information needed to assess that possibility.

The record does not state whether the secondary outcome analysis included all enrolled participants or used another analysis population. It also does not report an intention-to-treat definition or a plan for handling missing smoking follow-up data. As a result, the primary and secondary analysis populations cannot be fully characterized from the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The registry lists serious adverse events for four groups. The recorded serious adverse event count is 0 in each group, with 18, 19, 20, and 19 participants respectively listed as at risk. These are the counts entered in the registry record; they are not, by themselves, evidence that the groups have identical safety profiles or that serious events could not occur.

Other adverse events are recorded for 3 of 18 participants in the varenicline group, 6 of 19 in the nicotine-patches-only group, 6 of 20 in the varenicline-plus-bupropion group, and 4 of 19 in the post-quit NRT group. These are descriptive affected counts. No comparative statistical analysis or uncertainty estimates are reported, and no calculation of rates or between-group differences is made. The record does not provide the event terms in the serious-event listing.

The death entries are null, not numerical zeros. They therefore should not be read as a report of no deaths. The safety figures also refer to the listed at-risk participants and do not establish that all enrolled participants were included in these safety summaries. The registry record does not explain the relationship between these safety denominators and the total enrollment.

12. What the Result Does, and Does Not, Mean

This record describes a randomized, double-masked study designed to examine how pre-cessation treatments relate to brain responses to smoking cues. Its primary endpoint is an imaging measure collected after 2 weeks of pre-quit treatment and described as adjusted for baseline cue-reactivity. The study also lists days to first cigarette following quitting smoking as a secondary outcome. This design makes the endpoint mechanistic: it measures a response in brain imaging rather than directly measuring smoking abstinence as the primary outcome.

The registry does not report numerical primary-outcome results. It therefore does not establish whether the groups had different mean BOLD signal changes, how large any contrast was, or how precisely it was estimated. It also does not report a numerical result for days to first cigarette. No conclusion about the direction or magnitude of treatment effects on either outcome can be drawn from the recorded results.

Even if an imaging difference were reported, its meaning would depend on the treatment contrast, the specific region or regions analyzed, the size and uncertainty of the estimate, and the connection between the imaging response and a clinically meaningful outcome. An imaging response is not itself proof of smoking cessation or of a change in time to first cigarette. The registry does not report a numerical link between its primary and secondary outcomes.

The safety entries provide descriptive counts of serious and other adverse events among the listed at-risk participants. They do not provide enough information for a comparative safety conclusion. The serious adverse event counts are recorded as zero in the listed groups, but deaths are null, and no statistical comparisons or uncertainty estimates are reported.

Thus, the record is informative about the study’s broad question, design, endpoint, and eligibility rule for imaging analysis, but not about its primary efficacy result. A completed status indicates the study is recorded as completed; it does not fill in missing numerical findings or establish a treatment effect.

13. Why This Trial Matters Statistically

The study illustrates a statistical distinction between a mechanistic endpoint and a clinical outcome. Its primary measure is a brain-imaging response to smoking cues, while its listed secondary outcome concerns days to first cigarette after quitting. These outcomes address related but different questions. Keeping that distinction clear prevents an imaging measure from being treated as though it were itself a direct measure of quitting.

The endpoint also highlights why analysis populations matter. The imaging analysis included only participants who completed both scans and had usable data. That eligibility rule is part of the outcome definition in practice: the reported imaging estimate, if available, would describe the analyzed participants unless the analysis used an approach to account for missing observations. The registry does not report the analysis count or missing-data methods, limiting assessment of how representative that group was of all enrolled participants.

Adjustment for baseline cue-reactivity is another important statistical feature. In general, baseline adjustment can account for initial outcome differences and affect precision. But interpretation depends on the model and contrast, which are not reported. Without estimates and uncertainty measures, readers cannot distinguish a small, imprecise difference from a larger, more precisely estimated one.

The record also shows why completion and registration details should not be confused with results. It records a completed randomized study and gives treatment-group safety counts, yet contains no reported primary analysis. Study status and descriptive counts cannot substitute for a treatment-effect estimate with uncertainty. This is particularly important when a study has several named regions and treatment groups, since the intended comparison and approach to multiple testing affect interpretation.

For statistical readers, the central lesson is that a carefully described endpoint and design do not by themselves answer the research question. Interpretation requires the actual estimates, analysis population, model, and uncertainty measures. Those results are not reported in the registry record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting the findings is that numerical primary and secondary outcome results are not reported in the registry record. The record indicates zero analyses, and it provides no group means, treatment contrasts, measures of uncertainty, or p-values. The direction, magnitude, and precision of the primary imaging comparison therefore cannot be evaluated.

The imaging analysis was restricted to participants who completed both scanning sessions and provided usable data, but the number analyzed and the reasons for missing or unusable data are not reported. Group-specific analysis counts and any missing-data methods are also absent. This limits assessment of the population represented by the imaging analysis and whether exclusions could affect comparisons.

The primary endpoint refers to three brain regions, but the record does not specify whether each was analyzed separately or whether a combined measure was used. The number and ordering of planned treatment comparisons, multiplicity procedures, model details, and analysis plan are not reported. The arm descriptions are incomplete, so exact treatment schedules and placebo arrangements cannot be fully reconstructed.

The record does not report a sample-size justification for the trial. It describes planning assumptions for an illustration based on the observed effect, but no observed effect or numerical planning results are listed. The relationship between those assumptions and the trial’s actual design is therefore unclear.

Safety summaries are also limited: the at-risk counts vary across groups, no comparative uncertainty estimates are reported, and death entries are null. The record does not state how the safety population relates to total enrollment. These limitations mean the registry supports a description of study design and recorded counts, but not a comprehensive assessment of efficacy, missing-data impact, multiplicity, or comparative safety.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation — NCT01406223.
• Registry record last updated 2017-11-14; status last verified 2017-10.
• Results first posted 2017-08-31.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01406223 is a completed, randomized, double-masked, parallel-group phase 3 study sponsored by Duke University. It concerns nicotine dependence and records enrollment of 282. The study start is listed as 2011-07, with primary completion at 2013-12.

The primary endpoint is mean percent BOLD signal change during a cue-reactivity fMRI task after 2 weeks of pre-quit treatment, controlling for baseline cue-reactivity. The imaging analysis included participants who completed both scanning sessions and provided usable data. Days to first cigarette following quitting smoking is listed as a secondary outcome.

The registry record does not report numerical primary or secondary results, treatment contrasts, confidence intervals, or p-values. It records serious adverse event counts of 0 in each listed group; death entries are null. The record does not provide the detailed statistical analysis plan or the number of participants included in the imaging analysis.